Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders

Critical Reviews in Oncology/Hematology

Volumn 45, Issue 1, 2003, Pages 1-36

  Middeldorp, Jaap M ^a   Brink, Antoinette A T P ^a   Van den Brule, Adriaan J C ^a   Meijer, Chris J L M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carcinoma; Epstein Barr virus; Gene expression; Lymphoma; Pathogenesis

Indexed keywords

CD40 ANTIGEN; CELL ADHESION MOLECULE; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 3; EPSTEIN BARR VIRUS ANTIGEN 4; EPSTEIN BARR VIRUS ANTIGEN 5; EPSTEIN BARR VIRUS ANTIGEN 6; GENE PRODUCT; IMMUNOGLOBULIN HEAVY CHAIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN BCL 2; PROTEIN P53; RECEPTOR SUBTYPE; RECOMBINASE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; B LYMPHOCYTE ACTIVATION; BENIGN TUMOR; CARCINOMA; DISEASE ASSOCIATION; DNA BINDING; DNA SEQUENCE; DYSPROTEINEMIA; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE TRANSLOCATION; GERMINAL CENTER; GROWTH RATE; HUMAN; IN SITU HYBRIDIZATION; INFECTIOUS MONONUCLEOSIS; LATENT VIRUS INFECTION; LEUKOPLAKIA; LYMPHOEPITHELIOMA; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NORTHERN BLOTTING; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; OPEN READING FRAME; PATHOGENICITY; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SOUTHERN BLOTTING; STOMACH CARCINOMA; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE; VIRUS CARCINOGENESIS; VIRUS DETECTION; VIRUS GENE; VIRUS MORPHOLOGY; WESTERN BLOTTING; X CHROMOSOMAL INHERITANCE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS GENOME; VIRUS INFECTION;

EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, VIRAL; GENOME, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; VIRAL PROTEINS;

EID: 0037212399     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(02)00078-1     Document Type: Review

References (445)

1. Yunis J.J., Frizzera G., Oken M.M., McKenna J., Theologides A., Arnesen M. Multiple recurrent genomic defects in follicular lymphoma: a possible model for cancer. New Engl. J. Med. 316:1987;79-84.
2. Cleary M.L., Smith S.D., Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 47:1986;19-28.
3. Hockenberry D., Nunez G., Milliman C., Schreiber R.D., Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-348.
4. Limpens J., Stad R., Vos C., et al. Lymphoma-associated translocation t(14;18) in blood B-cells of normal individuals. Blood. 85:1995;2528-2536.
5. Dalla-Favera R., Bregni M., Erikson J., et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA. 79:1982;7824-7827.
6. Askew D.S., Ashmun R.A., Simmons B.C., Cleveland J.L. Constitutive c-myc expression in an IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene. 6:1991;1915-1922.
7. Magrath I.T. Concepts and controversies in lymphoid neoplasia. Magrath I.T. The non-Hodgkin's lymphomas. 1997;3-46 Arnold, London.
8. Kuppers R., Dalla-Favera R. Mechanisms of chromosomal translocations in B-cell lymphomas. Oncogene. 20:2001;5580-5594.
9. Goossens T., Klein U., Küppers R. Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. Proc. Natl. Acad. Sci. USA. 95:1998;2463-2468.
10. Lenoir G.M., Bornkamm G.W. Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: proposal for a new scenario. Adv. Viral Oncol. 7:1987;173-206.
11. Tamaru J., Hummel M., Marafioti T., et al. Burkitt's lymphomas express VH genes with a moderate number of antigen-selected somatic mutations. Am. J. Pathol. 147:1995;1398-1407.
12. Isaacson P.G. Gastric lymphoma and Helicobacter pylori. New Engl. J. Med. 330:1994;1310-1311.
13. Cerroni L., Zochling N., Putz B., Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J. Cutaneous Pathol. 24:1997;457-461.
14. Knowles D.M., Pirog E.C. Pathology of AIDS-related lymphomas and other AIDS-defining neoplams. Eur. J. Cancer. 37:2001;1236-1250.
15. Lam K.M., Syed N., White H., Crawford D.H. Circulating Epstein-Barr virus-carrying B-cells in acute malaria. Lancet. 337:(8746):1991;876-878.
16. Kuppers R., Rajewsky K. The origin of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Annu. Rev. Immunol. 16:1998;471-493.
17. Brink A.A.T.P., ten Berge R.L., van den Brule A.J.C., et al. Epstein-Barr virus is present in neoplastic cytotoxic T-cells in extranodal, and predominantly in B-cells in nodal T non-Hodgkin lymphomas. J. Pathol. 191:2000;400-406.
18. Kurth J., Spieker T., Wustrow J., et al. EBV infected B-cells in infectious mononucleosis: viral strategies for spreading in the B-cell compartment and establishment of latency. Immunity. 13:2000;485-495.
19. Brauniger A., Spieker T., Willenbrock K., et al. Survival and clonal expansion of mutating 'forbidden' (immunoglobulin receptor-deficient) Epstein-Barr virus B-cells in angioblastic T-cell lymphoma. J. Exp. Med. 194:2001;927-940.
20. Vogelstein B., Kinzler K.W. The multistep nature of cancer. Trends Genet. 9:1993;138-141.
21. Hague A., Moorghen M., Hicks D., Chapman M., Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene. 9:1994;3367-3370.
22. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
23. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
24. IARC Working group. Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses. Lyon: IARC Scientific publication, 1995.
25. Zur Hausen H., Schulte-Holthausen H., Klein G., et al. EBV-DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 228:1970;1056-1058.
26. Parkin D.M., Pisani P., Munoz N., Ferlay J. The global health burden of infection associated cancers. Cancer Surv. 33:1999;5-33.
27. Zur Hausen A., Brink A.A.T.P., Craanen M.E., et al. Unique transcription pattern of Epstein-Barr virus in EBV carrying gastric adeno-carcinomas: expression of the transforming gene BARF1. Cancer Res. 60:2000;2745-2748.
28. Raab-Traub N., Rajadurai P., Flynn K., Lanier A.P. Epstein-Barr virus infection in carcinoma of the salivary gland. J. Virol. 65:1991;7032-7036.
29. Sugawara Y., Mizugaki Y., Uchida T., et al. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology. 256:1999;196-202.
30. Bonnet M., Guinebretiere J.M., Kremmer E., et al. Detection of Epstein-Barr virus in invasive breast cancers. J. Natl. Cancer Inst. 16:1999;1376-1381.
31. Labreque L.G., Barnes D.M., Fentiman I.S., Griffin B.E. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res. 55:1995;39-45.
32. Brink A.A.T.P., van den Brule A.J.C., van Diest P.J., Meijer C.J.L.M. Re: detection of Epstein-Barr virus in breast cancer (letter). J. Natl. Cancer Inst. 92:2000;655-656.
33. Chu P.G., Chang K.L., Chen Y.Y., et al. No significant association of Epstein-Barr virus infection with invasive breast carcinoma. Am. J. Pathol. 159:2001;571-578.
34. Birkenbach M., Tong X., Badbury L.E., et al. Characterization of an Epstein-Barr virus receptor on human epithelial cells. J. Exp. Med. 176:1992;1405-1414.
35. Sixbey J.W., Yao Q.Y. Immunoglobulin A-induced shift of Epstein-Barr virus tropism. Science. 255:1992;1578-1580.
36. Molesworth S.J., Lake C.M., Borza C.M., Turk S.M., Hutt-Fletcher L.M. Epstein-Barr virus gH is essential for penetration of B-cells but also plays a role in attachment of virus to epithelial cells. J. Virol. 74:2000;6324-6332.
37. Roizman B. Herpesviridae: general description, taxonomy and classification. Roizman B. The herpesviruses. 1996;1-23 Plenum Press, London.
38. Wedderburn N., Edwards J.M.B., Desgranges C., Fontaine C., Cohen B., de Thé G. Infectious mononucleosis-like response in common marmosets infected with Epstein-Barr virus. J. Infect. Dis. 150:1984;878-882.
39. Kieff E. Epstein-Barr virus and its replication. Fields B.N., Knipe D.M., Howley P., et al. Fields virology. 1996;2343-2396 Lippincott-Raven, Philadelphia.
40. Baer R., Bankier A.T., Biggin M.D., et al. DNA sequence and expression of the B95.8 Epstein-Barr virus genome. Nature. 310:1984;207-211.
41. Sample J., Young L.S., Martin B., et al. Epstein-Barr virus types 1 and 2 differ in their EBNA3A, EBNA3B and EBNA3C genes. J. Virol. 64:1990;4084-4092.
42. Aitken C., Sengupta S.K., Aedes C., Moss D.J. Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus. J. Gen. Virol. 75:1994;95-100.
43. Habeshaw G., Yao Q.Y., Bell A.I., Morton D., Rickinson A.B. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographical areas. J. Virol. 73:1999;965-975.
44. Walling D.M., Shebib N., Weaver S.C., et al. The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane-1 protein. J. Infect. Dis. 179:1999;763-774.
45. Sacaze C., Henry S., Icart J., Mariame B. Tissue specific distribution of Epstein-Barr virus (EBV) BZLF1 gene variants in nasopharyngeal carcinoma (NPC) bearing patients. Virus Res. 81:2001;133-142.
46. Yao Q.Y., Rowe D.T., Martin B., Young L.S., Rickinson A.B. The Epstein-Barr virus carrier state: dominance of a single growth-transforming isolate in the blood and oropharynx of healthy virus carriers. J. Gen. Virol. 72:1998;1579-1590.
47. Fielding C.A., Sandvej K., Mehl A., et al. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signalling pathways. J. Virol. 75:2001;9129-9141.
48. Khanim F., Yao Q.Y., Niedobitek G., et al. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood. 88:1996;3491-3501.
49. Brink A.A.T.P., Oudejans J.J., Jiwa N.M., et al. Multiprimed cDNA synthesis followed by PCR is the most suitable method for Epstein-Barr virus transcript analysis in small lymphoma biopsies. Mol. Cell. Probes. 11:1997;39-47.
50. Brink A.A.T.P., Vervoort M.B.H.J., Middeldorp J.M., Meijer C.J.L.M., Van den Brule A.J.C. Nucleic acid sequence-based amplification, a new method for analysis of spliced and unspliced Epstein-Barr virus latent transcripts, and its comparison with reverse transcriptase PCR. J. Clin. Microbiol. 36:1998;3164-3169.
51. Katz B.Z., Raab-Traub N., Miller G. Latent and lytic forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J. Infect. Dis. 160:1989;589-598.
52. Ambinder R.F., Mann R.B. Detection and characterization of Epstein-Barr virus in clinical specimens. Am. J. Pathol. 145:1994;239-252.
53. Hsu D.W., De Waal Malefyt R., Fiorentino D.F., et al. Expression of interleukin 10 activity by Epstein-Barr virus protein BCRF1. Science. 250:1990;830-832.
54. Hayes D.P., Brink A.A.T.P., Vervoort M.B.H.J., Middeldorp J.M., et al. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Mol. Pathol. 52:(2):1999;97-103.
55. Howe J.G., Steitz J.A. Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization. Proc. Natl. Acad. Sci. USA. 83:1986;9006-9010.
56. Glickman J.N., Howe J.G., Steitz J.A. Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. J. Virol. 62:1988;902-911.
57. Arrand J.R. Expressed but enigmatic RNAs. EBV Rep. 7:2000;145-149.
58. Clemens M.L. Functional significance of the Epstein-Barr virus-encoded small RNAs. EBV Rep. 1:1994;107-111.
59. Toczyski D.P., Steitz J.A. EAP, a highly conserved cellular protein associated with Epstein-Barr virus small RNAs (EBERs). EMBO J. 10:1991;459-466.
60. Laing K.G., Matys V., Clemens M.J. Effects of expression of the Epstein-Barr virus small RNA EBER-1 in heterologous cells on protein synthesis and cell growth. Biochem. Soc. Trans. 23:1995;311S.
61. Yamamoto N., Takizawa T., Iwanaga Y., Shimizu N., Yamamoto N. Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded RNAs. FEBS Lett. 484:2000;153-158.
62. Sharp T.V., Raine D.A., Gewert D.R., et al. Activation of the interferon-inducible (2′-5′) oligoadenylate synthetase by the Epstein-Barr virus RNA EBER-1. Virology. 257:1999;303-313.
63. Takada K., Nanbo A. The role of EBERs in oncogenesis. Semin. Cancer Biol. 11:2001;461-467.
64. Bodescot M., Brison O., Perricaudet M. An Epstein-Barr virus transcription unit is at least 84 kb long. Nucleic Acids Res. 14:1986;2611-2620.
65. Woisetschlager M., Yandava C.N., Furmanski L.A., Strominger J.L., Speck S.H. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc. Natl. Acad. Sci. USA. 87:1990;1725-1729.
66. Schaefer B.C., Strominger J.L., Speck S.H. Host-cell determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol. Cell. Biol. 17:1998;364-377.
67. Schaefer B.C., Strominger J.L., Speck S.H. Redefining the Epstein-Barr virus encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc. Natl. Acad. Sci. USA. 92:1995;10565-10569.
68. Davenport M.G., Pagano J. Expression of EBNA1 mRNA is regulated by cell cycle during Epstein-Barr virus type-I latency. J. Virol. 73:1999;3154-3161.
69. Liang C.L., Tsai C.N., Chung P.J., et al. Transcription of Epstein-Barr virus encoded nuclear antigen 1 promoter Qp is repressed by transforming growth factor-β via Smad4 binding element in human BL cells. Virology. 277:2000;184-192.
70. Schaefer B.C., Strominger J.L., Speck S.H. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines. J. Virol. 69:1995;5039-5047.
71. Zettenberg H., Stenglein M., Jansson A., Ricksten A., Rymo L. Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus transformed lymphoid cells in latent and lytic stages of infection. J. Gen. Virol. 80:1999;457-465.
72. Ambinder R.F., Mullen M.A., Chang Y.N., Hayward G.S., Hayward S.D. Functional domains of Epstein-Barr virus nuclear antigen EBNA-1. J. Virol. 65:1991;1466-1478.
73. Chen M., Middeldorp J.M., Hayward S.D. Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structures. J. Virol. 67:1993;4875-4885.
74. Bochkarev A., Pfuetzner R.A., Edwards A.M., Frappier L. Structure of the single-stranded-DNA-binding domain of replication protein A bound to DNA. Nature. 385:(6612):1997;176-181.
75. Rawlins D.R., Milman G., Hayward S.D., Hayward G.S. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell. 42:1985;859-868.
76. Reisman D., Yates J., Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol. Cell. Biol. 5:1985;1822-1832.
77. Leight E.R., Sugden B. EBNA1: a protein pivotal to latent infection by Epstein-Barr virus. Rev. Med. Virol. 10:2000;83-100.
78. Goldsmith K., Bendell L., Frappier L. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J. Virol. 67:1993;3418-3426.
79. Wu H., Kapoor P., Frappier L. Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J. Virol. 76:2002;2480-2490.
80. Ohno S., Luka J., Falk L.A., Klein G. Identification of a purified complement-fixing antigen as the Epstein-Barr virus determined nuclear antigen (EBNA) by its binding to metaphase chromosomes. Proc. Natl. Acad. Sci. USA. 74:1977;1605-1609.
81. Wu H., Ceccarelli D.F., Frappier L. The DNA segregation mechanism of Epstein-Barr virus nuclear antigen 1. EMBO Rep. 1:2000;140-144.
82. Sample J., Henson D.E.B., Sample C. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated. J. Virol. 66:1992;4654-4661.
83. Huber M.D., Dworet J.H., Shire K., Frappier L., McLear M.A. The budding yeast homolog of the human EBNA1-binding protein 2 (Ebp2p) is an essential nucleolar protein required for pre-rRNA processing. J. Biol. Chem. 275:2000;28764-28773.
84. Chen M.R., Yang Y.F., Wu C.W., Middeldorp J.M., Chen J.Y. Physical association between the EBV protein EBNA-1 and P32/TAP/hyaluronectin. J. Biomed. Sci. 5:1998;173-179.
85. Wang Y., Finan J.E., Middeldorp J.M., Hayward S.D. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus. Virology. 236:1997;18-29.
86. van Scoy S., Watakabe I., Krainer A.R., Hearing J. Human p32: a co-activator for Epstein-Barr virus nuclear antigen-1 mediated transcriptional activation and possible role in viral latent cycle DNA replication. Virology. 275:2000;145-157.
87. Wilson J.B., Bell J.L., Levine A.J. Expression of Epstein-Barr virus nuclear antigen-1 induces B-cell neoplasia in trangenic mice. EMBO J. 15:1996;3117-3126.
88. Kuhn-Hallek I., Sage D.R., Stein L., Groelle H., Fingeroth J.D. Expression of recombination activating genes (RAG-1 and -2) in Epstein-Barr virus-bearing B-cells. Blood. 85:1995;1289-1299.
89. Srinivas S., Sixbey J.W. Epstein-Barr virus induction of recombinase-activating genes RAG1 and 2. J. Virol. 69:1995;8155-8158.
90. Levitskaya J., Coram M., Levitsky V., et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus antigen-1. Nature. 375:1995;685-688.
91. Leen A., Meij P., Redchenko I., Middeldorp J., et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J. Virol. 75:2001;8649-8659.
92. van Grunsven W., Nabbe A., Middeldorp J.M. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J. Med. Virol. 40:1993;161-169.
93. Blake N., Lee S., Redchenko I., et al. Human CD8+ T-cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity. 7:1997;791-802.
94. Blake N., Haigh T., Shaka'a G., Croom-Carter D., Rickinson A. The importance of exogenous antigen in priming the human CD8+ T-cell response: lessons from the EBV nuclear antigen EBNA1. J. Immunol. 165:2000;7078-7087.
95. Cordier M., Calender A., Billaud M., et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J. Virol. 64:1990;1002-1013.
96. Knutson J. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J. Virol. 64:1990;2530-2534.
97. Wang F., Tsang S.F., Kurilla M.G., Cohen J.I., Kieff E. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64:1991;3407-3416.
98. Tsang S.F., Wang F., Izumi K.M., Kieff E. Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression. J. Virol. 65:1991;6765-6771.
99. Sung N.S., Kenney S., Gutsch D., Pagano J.S. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J. Virol. 65:1991;2164-2169.
100. Henkel T., Ling P.D., Hayward S.D., Peterson M.G. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J-κ Science. 265:1994;92-95.
101. Hsieh J.J.-D., Henkel T., Salmon P., et al. Truncated mammalian Notch 1 activates CBF1/RBP J-κ-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol. Cell. Biol. 16:1996;952-959.
102. Zimber-Strobl U., Strobl L.J. EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes. Semin. Cancer Biol. 11:2001;423-434.
103. Sinclair A.J., Palmero I., Peters G., Farrell P.J. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:1994;3321-3328.
104. Rickinson A.B., Young L.S., Rowe M. Influence of the Epstein-Barr virus nuclear antigen EBNA2 on the growth phenotype of virus-transformed B-cells. J. Virol. 61:1987;1310-1317.
105. Cohen J.I., Wang, Mannick J., Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. USA. 86:1989;9558-9562.
106. Brink A.A.T.P., Dukers D.F., Van den Brule A.J.C., et al. Presence of Epstein-Barr virus latency type III at the single-cell level in post-transplantation lymphoproliferative disorders and AIDS-related lymphomas. J. Clin. Pathol. 50:1997;911-918.
107. Allday M., Crawford D.H., Griffin B.E. Epstein-Barr virus latent gene expression during the initiation of B-cell immortalization. J. Gen. Virol. 70:1989;1755-1764.
108. Dillner J., Kallin B., Alexander H., et al. An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc. Natl. Acad. Sci. USA. 83:1986;6641-6645.
109. McCann E.M., Kelly G.L., Rickinson A.B., Bell A.I. Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function. J. Gen. Virol. 82:2001;3067-3079.
110. Kitay M.K., Rowe D.T. Cell cycle stage-specific phosphorylation of the Epstein-Barr virus immortalizing protein EBNA-LP. J. Virol. 70:1996;7885-7893.
111. Hammerschmidt W., Sugden B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature. 340:1989;393-397.
112. Szekely L., Selivanova G., Magnusson K.P., Klein G., Wiman K.G. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA. 90:1993;5455-5459.
113. Han I., Harada S., Weaver D., et al. EBNA-LP associates with cellular proteins including DNA-PK and HA95. J. Virol. 75:2001;2475-2481.
114. Dufva M., Olsson M., Rymo L. Epstein-Barr virus nuclear antigen 5 interacts with HAX-1, a possible component of the B-cell receptor signalling pathway. J. Gen. Virol. 82:2001;1581-1587.
115. Hennessy K., Fennewald S., Kieff E. A third nuclear protein in lymphoblasts immortalized by Epstein-Barr virus. Proc. Natl. Acad. Sci. USA. 82:1985;5944-5948.
116. Petti L., Sample C., Kieff E. Subnuclear localization and phosphorylation of Epstein-Barr virus latent infection nuclear proteins. Virology. 176:1990;563-574.
117. Silins S.L., Sculley T.B. Modulation of vimentin, the CD40 activation antigen and Burkitt's lymphoma antigen (CD77) by the Epstein-Barr virus nuclear antigen EBNA-4. Virology. 202:1994;16-24.
118. Krauer K.G., Kienzle N., Young D.B., Sculley T.B. Epstein-Barr virus nuclear antigen 3 and 4 interact with RBP-2N, a major isoform of RBP J-κ in B-lymphocytes. Virology. 226:1996;346-353.
119. Krauer K.G., Buck M., Sculley T. Characterization of the transcriptional repressor RBP in Epstein-Barr virus-transformed B-cells. J. Gen. Virol. 80:1999;3217-3226.
120. Wang F., Gregory C., Sample C., et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:1990;2309-2318.
121. Allday M.J., Crawford D.H., Thomas J.A. Epstein-Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cells. J. Gen. Virol. 74:1993;361-369.
122. Lin J., Johannsen E., Robertson E., Kieff E. Epstein-Barr virus nuclear antigen 3C putative repression domain mediates co-activation of the LMP1 promoter with EBNA-2. J. Virol. 76:2002;232-242.
123. Radkov S.A., Bain M., Farrell P., et al. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21. J. Virol. 71:1997;8552-8562.
124. Parker G.A., Crook T., Bain M., et al. Epstein-Barr virus nuclear antigen (EBNA) 3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene. 13:1996;2541-2549.
125. Parker G.A., Touitou R., Allday M.J. Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene. 19:2000;700-709.
126. Wade M., Allday M.J. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol. Cell. Biol. 20:2000;1344-1360.
127. Liebowitz D., Wang G., Kieff E. Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J. Virol. 58:1986;233-237.
128. Moorthy R., Thorley-Lawson A. Processing of the Epstein-Barr virus encoded latent membrane protein p63/LMP. J. Virol. 64:1990;829-837.
129. Laszlo L., Tuckwell J., Self T., et al. The latent membrane protein-1 in Epstein-Barr virus-transformed lymphoblastoisd cells is found with ubiquitin-protein conjugates and heat-shock protein 70 in lysosomes oriented around the microtubule organizing center. J. Pathol. 164:1991;203-214.
130. Liebowitz D., Kopan R., Fuchs E., Sample J., Kieff E. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol. Cell. Biol. 7:1987;2299-2308.
131. Dukers D.F., Meij P., Vervoort M.B.H.J., et al. Direct immunosuppressive of Epstein-Barr virus latent membrane protein-1 in vitro. J. Immunol. 165:2000;663-670.
132. Bloss T., Kaykas A., Sugden B. Dissociation of patching by latent membrane protein-1 of Epstein-Barr virus from its stimulation of NF-κB activity. J. Gen. Virol. 80:1999;3227-3232.
133. Boos H., Berger R., Kuklik-Roos C., Iftner T., Mueller-Lantzsch N. Enhancement of Epstein-Barr virus membrane protein (LMP) expression by serum, TPA, or n-butyrate in latently infected Raji cells. Virology. 159:(1):1987;161-165.
134. Erickson K.D., Martin J.M. The late lytic LMP-1 protein of Epstein-Barr virus can negatively regulate LMP-1 signaling. J. Virol. 74:2000;1057-1060.
135. Peng M., Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B-cells induces cellular activation and DNA synthesis. Oncogene. 7:1992;1775-1782.
136. Floettmann J.E., Ward K., Rickinson A.B., Rowe M. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B-cell lines. Virology. 223:1996;29-40.
137. Kaykas A., Sugden B. The amino-terminus and membrane spanning domains of LMP1 inhibit cell proliferation. Oncogene. 19:2000;1400-1410.
138. Meij P., Vervoort M.B.H.J., Bloemena E., Meijer C.J.L.M., Middeldorp J.M. Production monitoring and immunoaffinity purification of EBV-encoded LMP1 expressed in recombinant Baculovirus-infected insect cells. J. Virol. Methods. 90:2000;193-204.
139. Young L.S., Dawson C.W., Clark D., et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 69:1988;1051-1065.
140. Jiwa N.M., Oudejans J.J., Dukers D.F., et al. Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases. J. Clin. Pathol. 48:1995;438-442.
141. de Bruin P.C., Jiwa N.M., van der Valk P., et al. Detection of Epstein-Barr virus nucleic acid sequences and protein in nodal T-cell lymphomas. Relationship between LMP1 positivity and clinical course. Histopathology. 23:1993;509-518.
142. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodents cells. Cell. 43:1985;831-840.
143. Rowe D.T. Epstein-Barr virus immortalization and latency. Front Biosci. 4:1999;346-371.
144. Henderson S., Rowe M., Gregory C., et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B-cells from programmed cell death. Cell. 65:1991;1107-1115.
145. Fries K.L., Miller W.E., Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J. Virol. 70:1996;8653-8659.
146. Nakagomi H., Dolcetti R., Bejarano M.T., Pisa P., Kiessling R., Masucci M.G. The Epstein-Barr virus latent membrane protein (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int. J. Cancer. 57:1994;240-244.
147. Kulwichit W., Hood Edwards R., Davenport E.M., Baskar J.F., Godfrey V., Raab-Traub N. Expression of the Epstein-Barr virus latent membrane protein 1 induces B-cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA. 95:1998;11963-11968.
148. Wilson J.B., Weinberg W., Johnson R., Yuspa S., Levine A.J. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of trangenic mice induces hyperplasia and aberrant expression of keratin 6. Cell. 61:1990;1315-1327.
149. Mosialos G., Birkenbach M., Yalamanchili R., VanArsdale T., Ware C., Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumor necrosis factor receptor family. Cell. 80:1995;389-399.
150. Liebowitz D. Epstein-Barr virus and a cellular signalling pathway in lymphomas from immunosuppressed patients. New Engl. J. Med. 338:1998;1413-1421.
151. Webster-Cyraque J., Middeldorp J.M., Raab-Traub N. Epstein-Barr virus latent membrane protein 1 underlies the pathology of oral hairy leukoplakia: an unusual combination of transformation and permissive infection. J. Virol. 74:2000;7610-7618.
152. Uchida J., Yasui T., Takaoka-Shichijo Y., et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science. 286:(5438):1999;300-303.
153. Eliopoulos A.G., Young L.S. LMP1 structure and signal transduction. Semin. Cancer Boil. 11:2001;435-444.
154. Kaykas A., Worringer K., Sugden B. CD40 and LMP1 both signal from lipid rafts but LMP1 assembles a distinct, more efficient signaling complex. EMBO J. 20:2001;2641-2654.
155. Mehl A.M., Floettmann J.E., Jones M., Brennan P., Rowe M. Characterization of intercellular adhesion molecule-1 regulation by Epstein-Barr virus-encoded latent membrane protein-1 identifies pathways that cooperate with nuclear factor kappa B to activate transcription. J. Biol. Chem. 276:2001;984-992.
156. Gires O., Kohlhuber F., Kilger E., et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 18:1999;3064-3073.
157. Clause B., Fizazi K., Walczak V., et al. High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells. Virology. 228:1997;285-293.
158. Higuchi M., Izumi K.M., Kieff E. Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc. Natl. Acad. Sci. USA. 98:2001;4675-4680.
159. Mosialos G. Cytokine signaling and Epstein-Barr virus-mediated cell transformation. Cytokine Growth Factor Rev. 12:2001;259-270.
160. Yoshizaki T., Horikawa T., Qing-Chun R., et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin. Cancer Res. 7:2001;1946-1951.
161. Dukers D.F., Jaspers L.H., Hayes D., et al. Quantitative immunohistochemical analysis of cytokine profiles and T-cell infiltrate in Epstein-Barr virus positive and negative cases of Hodgkin's disease. J. Pathol. 190:2000;143-149.
162. Dukers DF. Immune escape mechanisms and clinicopathological aspects in malignant lymphomas. Academic thesis. Amsterdam: Free University, 2001. ISBN 90-9014973-2.
163. Gruss H.J., Pinto A., Duyster J., Poppema S., Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol. Today. 18:1997;156-163.
164. Laux G., Perricaudet M., Farrell P.J. A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J. 7:1988;769-774.
165. Longnecker R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv. Cancer Res. 79:2000;175-200.
166. Caldwell R.G., Wilson J.B., Anderson S.J., Longnecker R. Epstein-Barr virus LMP2a drives B-cell development and survival in the absence of normal B-cell receptor signals. Immunity. 9:1998;405-411.
167. Longan L., Longnecker R. Epstein-Barr virus latent membrane protein 2A has no growth-altering effects when expressed in differentiating epithelia. J. Gen. Virol. 81:2000;2245-2252.
168. Caldwell R.G., Brown R.C., Longnecker R. Epstein-Barr virus LMP2a-induced B-cell survival in two unique classes of EμLMP2a transgenic mice. J. Virol. 74:2000;1101-1113.
169. Babcock G.J., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B-cell. Immunity. 13:2000;497-506.
170. Babcock G.J., Thorley-Lawson D.A. Tonsillar memory B-cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc. Natl. Acad. Sci. USA. 97:2000;12250-12255.
171. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1:2001;75-82.
172. Brooks L.A., Lear A.L., Young L.A., Rickinson A.B. Transcripts from the Epstein-Barr virus BamHI-A fragment are detectable in all three forms of virus latency. J. Virol. 67:1993;3182-3190.
173. Chen H., Smith P., Ambinder R.F., Hayward S.D. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B-cells from peripheral blood. Blood. 93:1999;3026-3032.
174. Hitt M.M., Allday M.J., Hara T., et al. EBV gene expression in an NPC related tumor. EMBO J. 8:1989;2639-2651.
175. Smith P.R., Gao Y., Karran L., Jones M.D., Snudden D., Griffin B.E. Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors. J. Virol. 67:1993;3217-3225.
176. Chen H.L., Lung M.M., Sham J.T., Choy D.T.K., Griffin B.E., Ng M.H. Transcription of the BamHI A region of the EBV genome in NPC tissues and B-cells. Virology. 191:1992;193-201.
177. Karran L., Gao Y., Smith P.S., Griffin B.E. Expression of a family of complementary-strand transcripts in Epstein-Barr virus infected cells. Proc. Natl. Acad. Sci. USA. 89:1992;8058-8062.
178. Gilligan K.J., Rajadura P., Lin J.C., et al. Expression of the Epstein-Barr virus BamHI-A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J. Virol. 65:1991;6252-6259.
179. Sadler R.H., Raab-Traub N. Structural analyses of the Epstein-Barr virus BamHI-A transcripts. J. Virol. 69:1995;1132-1141.
180. Fries K.L., Sculley T.B., Webster-Cyriaque J., et al. Identification of a novel protein encoded by the BamHI A region of the Epstein-Barr virus. J. Virol. 71:1997;2765-2771.
181. Kienzle N., Sculley T.B., Poulsen L., et al. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression. J. Virol. 72:1998;6614-6620.
182. Kienzle N., Sculley T.B., Greco s Khanna R. Silencing virus-specific cytotoxic T-cell recognition by differential splicing: a novel implication of RNA processing for antigen processing. J. Immunol. 162:1999;6963-6966.
183. van Beek J, Brink AATP, Vervoort MBHJ, et al. Transcription of the Epstein-Barr virus (EBV) BAMHI-A region without (RK-)BARF0 protein expression in vivo in EBV-associated disorders, J. Virol 2002; submitted for publication.
184. Kienzle N., Buck M., Greco S., Krauer K., Sculley T.B. Epstein-Barr virus-encoded RK-BARF0 protein expression. J. Virol. 73:1999;8902-8906.
185. Kusano S., Raab-Traub N. An Epstein-Barr virus protein interacts with Notch. J. Virol. 75:2001;384-395.
186. Smith P. Epstein-Barr virus complementary strand transcripts (CSTs/BARTs) and cancer. Sem. Cancer Biol. 11:2001;469-476.
187. Smith P.R., de Jesus O., Turner D., et al. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J. Virol. 74:2000;3082-3092.
188. Zhang J., Chen H.L., Weinmaster G., Hayward S.D. Epstein-Barr virus BanmHI-A rightward transcript encoded RPMS protein interacts with CBF1-associated corepressor CIR to negatively regulate the activity of EBNA2 and Notch IC. J. Virol. 75:2001;2945-2956.
189. Zhang C.X., Decaussin G., Daillie J., Ooka T. Altered expression of two Epstein-Barr virus early genes localized in BamHI-A in nonproducer Raji cells. J. Virol. 62:1988;1862-1869.
190. Sbih-Lammali F., Djennaoui D., Belaoui D., Bouguermouth A., Decaussin G., Ooka T. Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma. J. Med. Virol. 49:1996;7-14.
191. zur Hausen A., Brink A.A.T.P., Craanen M.E., et al. Unique transcription pattern of Epstein-Barr virus in EBV-carrying gastric adenocarcinomas: expression of the transforming gene BARF1. Cancer Res. 60:2000;2745-2748.
192. Decaussin G., Sbih-Lammali F., de Turenne-Tessier M., Bouguermouh A., Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res. 60:2000;5584-5588.
193. Wei M.X., Moulin J.C., Decoussin G., Berger F., Ooka T. Expression and tumorigenicity of the Epstein-Barr virus BARF1 gene in human Louckes B-lymphocyte cell line. Cancer Res. 54:(7):1994;1843-1848.
194. Wei M.X., Deturenne-Tessier M., Decaussin G., Benet G., Ooka T. Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus. Oncogene. 14:1997;3073-3081.
195. Sheng W., Decaussin G., Sumner S., Ooka T. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene. 20:2001;1176-1185.
196. Strockbine L.D., Cohen J.I., Farrah T., et al. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor. J. Virol. 72:1998;4015-4021.
197. Chang Y.N., Dong D.L.Y., Hayward G.S., Hayward S.D. The Epstein-Barr virus Zta transactivator: a member of the bZIP family with unique DNA-binding specificity and a dimerization domain that lacks the characteristic heptad leucine zipper motif. J. Virol. 64:1990;3358-3369.
198. Zhang Q., Gutsch D., Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1994;1929-1938.
199. Li J.-H., Huang D., Sun B.-F., Middeldorp J.M., et al. The effect of ionizing radiation combined with adenoviral p53 therapy in EBV-positive nasopharyngeal carcinoma. Int. J. Cancer. 7:2000;606-611.
200. Pallesen G., Hamilton-Dutoit S.J., Rowe M., et al. Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells. J. Pathol. 165:1991;289-299.
201. Oudejans J.J., Jiwa N.M., van den Brule A.J.C., et al. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplant lymphoproliferative disorders. Am. J. Pathol. 147:1995;923-933.
202. Martel-Renoir D., Grunewald V., Touitou R., Schwaab G., Joab I. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J. Gen. Virol. 76:1995;1401-1408.
203. Morrison T.E., Mauser A., Wong A., Ting J.P.Y., Kenney S.C. Inhibition of IFNγ signalling by an Epstein-Barr virus immediate early protein. Immunity. 15:2001;787-799.
204. Segouffin-Cariou C., Farjot G., Sergeant A., Gruffat H. Characterization of the Epstein-Barr virus BRRF1 gene, located between early genes BZLF1 and BRLF1. J. Gen. Virol. 81:2000;1791-1799.
205. Bar-Ner M, Thibault A, Tsokos M, Magrath IT, Samid D. Phenyl butyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells, Clin. Cancer Res. 1999; 1509-16.
206. Faller D.V., Mentzner S.J., Perrine S.P. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr. Opin. Oncol. 13:2001;360-367.
207. Pearson G.R., Luka J., Petti L., et al. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology. 160:1987;151-161.
208. Alfieri C., Birkenbach M., Kieff E. Early events in Epstein-Barr virus infection of human B lymphocytes. Virology. 181:1991;595-608.
209. Austin P.J., Flemington E., Yandawa C.N., Strominger J.L., Speck S.H. Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphcytes. Proc. Natl. Acad. Sci. USA. 85:1988;3678-3682.
210. Oudejans J.J., Van den Brule A.J.C., Jiwa N.M., et al. BHRF1, the Epstein-Barr virus (EBV) homologue of the bcl-2 (proto-)oncogene, is transcribed in EBV associated B-cell lymphomas and in reactive lymphocytes. Blood. 86:1995;1893-1902.
211. Murray P.G., Swinnen L.J., Constandinou C.M., et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood. 87:(2):1996;706-711.
212. Nicholls J., Kremmer E., Meseda C.A., et al. Comparative analysis of the expression of the Epstein-Barr virus (EBV) anti-apoptotic gene BHRF1 in nasopharyngeal carcinoma and EBV-related lymphoid diseases. J. Med. Virol. 65:2001;105-113.
213. Henderson S., Huen D., Rowe M., et al. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of bcl-2, protects human B-cells from programmed cell death. Proc. Natl. Acad. Sci. USA. 90:1993;8479-8483.
214. Takayama S., Cazalshatem D.L., Kitada S., et al. Evolutionary conservation of function among mammalian, avian, and viral homologs of the Bcl-2 oncoprotein. DNA Cell Biol. 13:1994;679-692.
215. Williams T., Sale D., Hazlewood S.A. BHRF1 is highly conserved in primate virus analogues of Epstein-Barr virus. Intervirology. 44:2001;55-58.
216. Young L.S., Dawson C.W., Eliopoulos A.G. Epstein-Barr virus and apoptosis: viral mimicry of cellular pathways. Biochem. Soc. Trans. 27:1999;807-812.
217. van Grunsven W., Nabbe A., Middeldorp J.M. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J. Med. Virol. 40:1993;161-169.
218. van Grunsven W.M.J., Spaan W.J.M., Middeldorp J.M. Localization and diagnostic application of immundominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J. Infect. Dis. 170:1994;13-19.
219. Thorley-Lawson D.A., Poodry C.A. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J. Virol. 43:1982;730-736.
220. Moore K.W., Vieira P., Fiorentino D.F., Trounstine M.L., Khan T.A., Mosmann T.R. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science. 248:1990;1230-1234.
221. Moore K.W., Rousset F., Banchereau J. Evolving principles in immunopathology: interleukin-10 and its relationship to Epstein-Barr virus protein BCRF1. Springer Semin. Immunopathol. 13:1991;157-166.
222. Muller A., Schmitt L., Raftery M., Schonrich G. Paralysis of B7 co-stimulation through the effect of viral IL-10 on T-cells as a mechanism of local tolerance induction. Eur. J. Immunol. 28:1998;3488-3498.
223. Fujieda S., Lee K., Sunaga H., et al. Staining of interleukin-10 predicts clinical outcome in patients with nasopharyngeal carcinoma. Cancer. 85:1999;1439-1445.
224. Sarris A.H., Kliche K.O., Pethambaram P., et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann. Oncol. 10:1999;433-440.
225. Garnier J.L., Blanc-Brunat N., Vivier G., Rousset F., Touraine J.L. Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas. Clin. Transplant. 13:1999;305-312.
226. Faulkner G.C., Burrows S.R., Khanna R., Moss D.J., Bird A.G., Crawford D.H. X-linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implication for the biology of the virus. J. Virol. 73:1999;1555-1564.
227. Tanner J., Weis J., Fearon D., Whang Y., Kieff E. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. Cell. 50:1987;203-213.
228. Fingeroth J.D., Weis J.J., Tedder T.F., Strominger J.L., Biro P.A., Fearon D.T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA. 81:1984;4510-4514.
229. D'Addario M., Libermann T.A., Xu J., Ahmad A., Menezes J. Epstein-Barr virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways. J. Mol. Biol. 308:2001;501-514.
230. Sixbey J.W., Pagano J.S. Epstein-Barr virus transformation of human B lymphocytes despite inhibition of viral polymerase. J. Virol. 53:1985;299-301.
231. Hurley E.A., Thorley-Lawson D.A. B-cell activation and the establishment of Epstein-Barr virus latency. J. Exp. Med. 168:1988;2059-2075.
232. Matsuo T., Heller M., Petti L., O'Shiro E., Kieff E. Persistence of the entire Epstein-Barr virus genome integrated into the human lymphocyte DNA. Science. 226:1984;1322-1325.
233. Hurley E.A., Agger S., McNeil J.A., et al. When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates. J. Virol. 65:1991;1245-1254.
234. Ohshima K., Suzumiya J., Kanda M., Kato A., Kikuchi M. Integrated and episomal forms of Epstein-Barr virus (EBV) in EBV associated disease. Cancer Lett. 122:1998;43-50.
235. Tierney R., Steven N., Young L., Rickinson A. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:(11):1994;7374-7385.
236. Thorley-Lawson D.A., Miyashita E.M. Epstein-Barr virus and the B-cell: that's all it takes. Trends Microbiol. 4:1996;204-208.
237. Niedobitek G., Agathanggelou A., Steven N., Young L.S. Epstein-Barr virus (EBV) in infectious mononucleosis: detection of the virus in tonsillar B lymphocytes but not in desquamated oropharyngeal epithelial cells. Mol. Pathol. 53:2000;37-42.
238. Klein E., Ernberg I., Masucci M.G., et al. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis. Cancer Res. 41:1981;4210-4215.
239. Bharadwaj M., Burrows S.R., Burrows J.M., Moss D.J., Catalina M., Khanna R. Longitudinal dynamics of antigen-specific CD8+ cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood. 98:2001;2588-2589.
240. Khanna R., Burrows S.R. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54:2000;19-48.
241. Rickinson A.B., Kieff E. Epstein-Barr virus. Fields B.N., Knipe D.M., Howley P.M. Fields virology. 1996;2397-2476 Lippincott-Raven, Philadelphia.
242. Thorley-Lawson D.A., Babcock G.J. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B-cells. Life Sci. 65:1999;1433-1453.
243. Rickinson A., Lane P.J.L. Epstein-Barr virus: co-opting B-cell memory and migration. Curr. Biol. 10:2000;R120-R123.
244. Gratama J.W., Oosterveer M.A.P., Zwaan F.E., Lepoutre J., Klein G., Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc. Natl. Acad. Sci. USA. 85:1988;8693-8696.
245. Miyashita E.M., Yang B., Lam K.M.C., Crawford D.H., Thorley-Lawson D.A. A novel form of Epstein-Barr virus latency in normal B-cells in vivo. Cell. 80:1995;593-601.
246. Joseph A.M., Babcock G.J., Thorley-Lawson D.A. Cells Expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J. Virol. 74:2000;9964-9971.
247. Joseph A.M., Babcock G.J., Thorley-Lawson D.A. EBV persistence involves strict selection of latently infected B-cells. J. Immunol. 165:2000;2975-2981.
248. Qu L., Rowe D.T. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66:1992;3715-3724.
249. Masucci M.G., Ernberg I. Epstein-Barr virus: adaption to a life within the immune system. Trends Microbiol. 2:1994;125-130.
250. Tierney R.J., Kirby H.E., Nagra J.K., et al. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation. J. Virol. 74:2000;10468-10479.
251. Salamon D., Takacs M., Ujvari D., et al. Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus. J. Virol. 75:2001;2584-2596.
252. Niedobitek G., Herbst H., Young L.S., et al. Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood. 79:1992;2520-2526.
253. Anagnostopoulos I., Hummel M., Kreschel C., Stein H. Morphology, immunophenotype and distribution of latently and/or productively Epstein-Barr virus infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood. 85:1995;744-750.
254. Nakayama T., Fujisawa R., Izawa D., et al. Human B-cells immortalized with Epstein-Barr virus upregulate CCR6 and CCR10 and downregulate CxCR4 and CXCR5. J. Virol. 76:2002;3072-3077.
255. Henle W., Henle G. The sero-epidemiology of Epstein-Barr virus. Adv. Pathobiol. 5:1976;5-17.
256. Raab Traub N., Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal proliferation. Cell. 47:1986;883-889.
257. Saiki R., Scharf S., Faloona F., et al. Enzymatic amplification of beta-globin genomic sequences and restriction analysis for diagnosis of sickle cell anemia. Science. 230:1985;1350-1354.
258. Stevens S.J.C., Vervoort M.B.H.J., Meijer C.J.L.M., et al. Monitoring of Epstein-Barr virus load by quantitative competitive polymerase chain reaction. J. Clin. Microbiol. 37:1999;2852-2857.
259. Niesters H.G., van Esser J., Fries E., Wolthers K.C., Cornelissen J., Osterhaus A.D. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J. Clin. Microbiol. 38:2000;712-715.
260. Stevens S.J.C., Verschuuren E.A.M., Pronk I., et al. Early detection of posttransplant lymphoproliferative disease: the relevance of weekly monitoring of Epstein-Barr virus load in peripheral blood. Blood. 97:2001;1165-1171.
261. Stevens S.J.C., Verschuuren E.A.M., Verkuijlen S.A., et al. Role of Epstein-Barr virus DNA load monitoring in early detection and prevention of post-transplant lymphoproliferative disease. Leuk. Lymphoma. 43:2002;831-840.
262. Fan H., Gulley M.L. Epstein-Barr viral load monitoring as a marker of EBV-related disease. Mol. Diagn. 6:2001;279-289.
263. Wu T.C., Mann R.B., Charache P., et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int. J. Cancer. 46:1990;801-804.
264. Hamilton Dutoit S.J., Pallesen G. Detection of Epstein-Barr virus small RNAs in routine paraffin sections using non-isotopic RNA/RNA in situ hybridization. Histopathology. 25:1994;101-111.
265. Zhang J.X., Chen H.L., Zong Y.S., et al. The Epstein-Barr virus lytic life cycle associating with nasopharyngeal carcinoma keratinization. J. Med. Virol. 35:1998;227-236.
266. Oudejans J.J., Dukers F.F., van Gorp J., et al. Expression of Epstein-Barr virus (EBV) encoded nuclear antigen-1 (EBNA-1) in benign and malignant EBV harbouring tissues. J. Clin. Pathol. 49:1996;897-902.
267. Grässer F.A., Murray P.G., Kremmer E., et al. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood. 84:1994;3792-3798.
268. Wagner H.J., Hornef M., Middeldorp J.M., Kirchner H. Characteristics of viral protein expression of Epstein-Barr virus infected B lymphocytes in peripheral blood of patients with active or latent EBV infection. Clin. Diagn. Lab. Immunol. 2:1995;696-699.
269. Rowe M., Mehl A. Antibodies for detecting EBV latent proteins. Wilson J.B., May G.H.W. Methods in molecular biology Epstein-Barr virus protocols. 174:2001;219-228 Humana Press, Clifton, UK.
270. Compton J. Nucleic acid sequence-based amplification. Nature. 350:1991;91-92.
271. Kremmer E., Kranz B.R., Hille A., et al. Rat monoclonal antibodies differentiating between the Epstein-Barr virus nuclear antigens 2A (EBNA2A) and 2B (EBNA2B). Virology. 208:1995;336-342.
272. Niedobitek G., Kremmer E., Herbst H., et al. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and mononucleosis. Blood. 90:1997;1664-1672.
273. Young L.S., Lau R., Rowe M., et al. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J. Virol. 65:1991;2868-2874.
274. Zeng Y., Middeldorp J.M., Madjar J.J., Ooka T. A major DNA binding protein encoded by BALF2 open reading frame of Epstein-Barr virus (EBV) forms a complex with other EBV DNA-binding proteins: DNAase, EA-D and DNA polymerase. Virol. 239:1997;285-295.
275. Lau R., Middeldorp J.M., Farrell P. Epstein-Barr virus gene expression in oral hairy leukoplakia. Virology. 195:1993;463-474.
276. Evans A.S. Clinical syndromes associated with EB virus infection. Adv. Intern. Med. 18:1972;77-93.
277. Brown N.A., Liu C., Garcia C.R., et al. Clonal origins of lymphoproliferative disease induced by Epstein-Barr virus. J. Virol. 58:1986;975-978.
278. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B-cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc. Natl. Acad. Sci. USA. 72:1975;1622-1626.
279. Niedobitek G., Agathangelou A., Herbst H., et al. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J. Pathol. 182:1997;151-159.
280. Skare J.C., Milunsky A., Byron K.S., Sullivan J.L. Mapping the X-linked lymphoproliferative syndrome. Proc. Natl. Acad. Sci. USA. 84:1987;2015-2018.
281. Morra M., Simarro-Grande M., Martin M., et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J. Biol. Chem. 276:2001;36809-36816.
282. Sayos J., Wu C., Morra M., et al. The X-linked lymphoproliferative disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 395:1998;462-469.
283. Latour S., Gish G., Helgason C.D., et al. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat. Immunol. 2:2001;681-690.
284. Provisor A.J., Iacuone J.J., Chilcote R.R., et al. Acquired agammaglobulinemia after a life-threatening illness with clinical and laboratory features of infectious mononucleosis in three related male children. New Engl. J. Med. 293:1975;62-65.
285. Williams L.L., Rooney C.M., Conley M.E., et al. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet. 342:1993;587-588.
286. Seemayer T.A., Gross T.G., Maarten Egeler R., et al. X-linked lymphoproliferative disease: 25 years after the discovery. Pediatr. Res. 38:1995;471-478.
287. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf. 23:2000;101-113.
288. Hopwood P., Crawford D.H. The role of EBV in post-transplant malignancies: a review. J. Clin. Pathol. 53:2000;248-254.
289. Nelson B.P., Nalesnik M.A., Bahler D.W., et al. Epstein-Barr virus negative post-transplant lymphoproliferative disorders: a distinct entity. Am. J. Surg. Pathol. 24:2000;375-385.
290. Knowles D.M., Cesarman E., Chadburn A., et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood. 85:1995;552-565.
291. Haque T., Crawford D.H. Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders. Springer Semin. Immunopathol. 20:1998;375-387.
292. Knowles D.M. Immunodeficiency-associated lymphoproliferative disorders. Mod. Pathol. 12:1999;200-217.
293. Young L., Alfieri C., Hennessy K., et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. New Engl. J. Med. 321:1989;1080-1085.
294. Gratama J.W., Zutter M.M., Minarovits J., et al. Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients. Int. J. Cancer. 47:1991;188-192.
295. Perera S.M., Thomas J.A., Burke M., Crawford D.H. Analysis of the T-cell micro-environment in Epstein-Barr virus-related post-transplantation B lymphoproliferative disease. J. Pathol. 184:1998;177-184.
296. Savoldo B., Heslop H.E., Rooney C.M. The use of cytotoxic T-cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients. Leuk. Lymphoma. 39:2000;455-464.
297. Rooney C.M., Aguilar L.K., Huls M.H., Brenner M.K., Heslop H.E. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr. Top. Microbiol. Immunol. 258:2001;221-229.
298. Haque T., Amlot P.L., Helling N., et al. Reconstitution of EBV-specific T-cell immunity in solid organ transplant recipients. J. Immunol. 160:1998;6204-6209.
299. Orentas R.J., Lemas M.V., Mullin M.J., et al. Feasibility of cellular adoptive immunotherapy for Epstein-Barr virus-associated lymphomas using haploidentical donors. J. Hematother. 7:1998;257-261.
300. Savoldo B., Goss J., Liu Z., et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T-cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 72:2001;1078-1086.
301. van Esser J.W.J., Niesters H.G.M., van der Holt B., et al. Prevention of Epstein-Barr virus lymphoproliferative disease by molecular monitoring and pre-emptive rituximab in high-risk patients after allogenic stem cell transplantation. Blood. 99:2002;4364-4369.
302. Verschuuren E.A.M., Stevens S.J.C., van Imhoff G.W., et al. Treatment of post-transplant lymphoproliferative disease with Rituximab: the remission, the relapse and the complication. Transplantation. 73:2002;100-104.
303. DeMario M.D., Liebowitz D.N. Lymphomas in the immunocompromised patient. Semin. Oncol. 25:1998;492-502.
304. Boyle M.J., Sewell W.A., Sculley T.B., et al. Subtypes of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood. 78:1991;3004-3011.
305. Yao Q.Y., Tierney R.J., Croom-Carter D., et al. Frequency of multiple Epstein-Barr virus infections in T-cell immunocompromised individuals. J. Virol. 70:1996;4884-4894.
306. van Baarle D., Hovenkamp E., Kersten M.J., et al. Direct Epstein-Barr virus (EBV) typing on peripheral blood mononuclear cells: no association between EBV type 2 infection or superinfection and the development of acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Blood. 93:1999;3949-3955.
307. Neri A., Barriga F., Inghirami G., et al. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood. 77:1991;1092-1095.
308. Hamilton Dutoit S.J., Pallesen G., Franzmann M.B., et al. AIDS-related lymphoma. Histopathology, immunophenotype and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am. J. Pathol. 138:1991;149-163.
309. Shibata D., Weiss L.M., Hernandez A.M., et al. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 81:1993;2102-2109.
310. Hamilton-Dutoit S.J., Rea D., Raphael M., et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am. J. Pathol. 143:1993;1072-1085.
311. Gaidano G., Dalla-Favera R. Molecular pathogenesis of AIDS-related lymphomas. Adv. Cancer Res. 67:1995;113-153.
312. Gaidano G., Capello D., Gloghini A., et al. Bcl-6 in AIDS-related lymphomas: pathogenetic and histogenetic implications. Leuk. Lymphoma. 31:1998;39-46.
313. Burkitt D., O'Conor G.T. Malignant lymphoma in African children. I.A clinical syndrome. Cancer. 14:1961;258-269.
314. Berard C.W., O'Conor G., Thomas L.B., et al. Histopathological definition of Burkitt's tumor. Bull. WHO. 40:1969;601-607.
315. Magrath I., Jain V., Bhatia K. Epstein-Barr virus and Burkitt's lymphoma. Sem. Cancer Biol. 3:1992;285-295.
316. Schaefer B.C., Woisetschlaeger M., Strominger J.L., Speck S.H. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc. Natl. Acad. Sci. USA. 88:1991;6550-6554.
317. Rowe D.T., Rowe M., Evan G.J., Wallace L.E., Farrell P.J., Rickinson A.B. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J. 5:1986;2599-2607.
318. Niedobitek G., Agathanggelou A., Rowe M., et al. Heterogenous expression of Epstein-Barr virus latent protein in endemic Burkitt's lymphoma. Blood. 86:(2):1995;659-665.
319. Zech L., Haglund U., Nilsson K., et al. Characteristic chromosomal abnormalities in biosies and lymphoid cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer. 17:1976;47-56.
320. Meru N., Jung A., Lisner R., Niedobitek G. Expression of the recombination activating genes (RAG1 and 2) is not detectable in Epstein-Barr virus-associated human lymphomas. Int. J. Cancer. 92:2001;75-78.
321. Hummel M., Anagnostopoulos I., Korbjuhn P., Stein H. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J. Pathol. 175:1995;263-271.
322. Oudejans J.J., Jiwa N.M., van den Brule A.J., Meijer C.J. Epstein-Barr virus and its possible role in the pathogenesis of B-cell lymphomas. Crit. Rev. Oncol. Hematol. 25:1997;127-138.
323. Fukayama M., Ibuka T., Hayashi Y. Epstein-Barr virus in pyothorax-associated pleural lymphomas. Am. J. Pathol. 143:1993;1044-1049.
324. Sasajima Y., Yamabe H., Kobashi Y. High expression of the Epstein-Barr virus latent protein EB nuclear antigen-2 on pyothorax-associated lymphomas. Am. J. Pathol. 143:1993;1280-1285.
325. Yamato H., Ohshima K., Suzumiya J., Kikuchi M. Evidence for local immunosuppression and demonstration of c-myc amplification in pyothorax-associated lymphoma. Histopathology. 39:2001;163-171.
326. Meijer C.J., Jiwa N.M., Dukers D.F., et al. Epstein-Barr virus and human T-cell lymphomas. Semin. Cancer Biol. 7:1996;191-196.
327. Fischer R., Delibrias C., Kazatchkine M.D. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 146:1991;865-869.
328. Hamilton Dutoit S.J., Pallesen G. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. Am. J. Pathol. 140:1992;1315-1325.
329. De Bruin P.C., Jiwa M., Oudejans J.J., et al. Presence of Epstein-Barr virus in extranodal T-cell lymphomas: differences in relation to site. Blood. 83:1994;1612-1618.
330. Kanavaros P., Lescs M.C., Brière J., et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood. 81:1993;2688-2695.
331. De Bruin P.C., Jiwa N.M., Oudejans J.J., Radaszkiewicz T., Meijer C.J.L.M. Epstein-Barr virus (EBV) in primary gastrointestinal T-cell lymphomas: association with gluten-sensitive enteropathy, pathological features and immunophenotype. Am. J. Pathol. 146:1995;861-867.
332. Felgar R.E., Macon W.R., Kinney M.C., Roberts S., Pasha T., Salhany K.E. TIA-1 expression in lymphoid neoplasms. Identification of subsets with CTL or NK cell differentiation. Am. J. Pathol. 150:1997;1893-1900.
333. De Bruin P.C., Connolly C.E., Oudejans J.J., et al. Enteropathy-associated T-cell lymphomas have a cytotoxic T-cell phenotype. Histopathology. 31:1997;131-317.
334. Brink A.A.T.P., ten Berge R.L., van den Brule A.J.C., et al. Epstein-Barr virus is present in neoplastic cytotoxic T-cells in extranodal, and predominantly in B-cells in nodal T non-Hodgkin lymphomas. J. Pathol. 191:2000;400-406.
335. Imai S., Nishikawa J., Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J. Virol. 72:1998;4371-4378.
336. Shen L., Chiang A.K., Liu W.P., et al. Expression of HLA class I, beta(2)-microglobulin, TAP1 and IL-10 in Epstein-Barr virus-associated nasal NK/T-cell lymphoma: implications for tumor immune escape mechanism. Int. J. Cancer. 92:2001;692-696.
337. Weiss L.M., Strickler J.G., Dorfman R.F., Horning S.J., Warnke R.A., Sklar J. Clonal T-cell populationsin angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am. J. Pathol. 122:1986;392-397.
338. Abruzzo L.V., Schmidt K., Weiss L.M., et al. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood. 82:(1):1993;241-246.
339. Smith J.L., Hodges E., Quin C.T., McCarthy K.P., Wright D.H. Frequent T and B-cell oligoclones in histologically and immunophenotypically characterized angioimmunoblastic lymphadenopathy. Am. J. Pathol. 156:2000;661-669.
340. Matsue K., Itoh M., Tsukuda K., Kokubo T., Hirose Y. Development of Epstein-Barr virus associated B-cell lymphoma after intensive treatment of patients with angioimmunoblastic lymphadenopathy with dysproteinemia. Int. J. Hematol. 67:(3):1998;319-329.
341. Herbst H., Dallenbach F., Hummel M., et al. Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30) positive anaplastic large cell lymphomas. Blood. 78:1991;2666-2673.
342. Ott G., Ott M., Feller A.C., Seidl S., Müller-Hermelink H.K. Prevalence of Epstein-Barr virus DNA in different T-cell lymphoma entities in a European population. Int. J. Cancer. 51:1992;562-567.
343. Kummer J.A., Vermeer M.H., Dukers D., Meijer C.J., Willemze R. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J. Invest. Dermatol. 109:1997;636-640.
344. Dukers D.F., Ten Berge R.L., Oudejans J.J., et al. A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. J. Clin. Pathol. 52:1999;129-136.
345. Lukes R.J., Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 26:1966;1063-1081.
346. Marafioti T., Hummel M., Anagnostopoulos I., et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B-cells. New Engl. J. Med. 337:1997;453-458.
347. Jarrett A.F., Armstrong A.A., Alexander E. Epidemiology of EBV and Hodgkin's disease. Ann. Oncol. 7:1996;S5-S10.
348. World Health Organization/International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8, vol. 70. Geneva: IARC Press, 1997.
349. Glaser S.L., Lin R.J., Stewart S.L., et al. Epstein-Barr virus associated Hodgkin's disease: epidemiologic characteristics in international data. Int. J. Cancer. 70:1997;375-382.
350. Ambinder R.F. Gammaherpesviruses and 'hit-and-run' oncogenesis. Am. J. Pathol. 156:2000;1-3.
351. Meij P, Vervoort MBHJ, Bloemena E, et al. Antibody responses to Epstein-Barr virus encoded latent membrane protein -1 (LMP1) and expression of LMP1 in juvenile Hodgkin's Disease, J. Med. Virol. 2002; in press.
352. Anagnostopoulos I., Herbst H., Niedobitek G., Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1 positive anaplastic large cell lymphoma by combined southern blot and ISH. Blood. 74:1989;810-816.
353. Wu T.C., Mann R.B., Charache P., et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int. J. Cancer. 46:1990;801-804.
354. Weinreb M., Day P.J., Niggli F., et al. The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Arch. Dis. Child. 74:1996;27-31.
355. Oudejans J.J., Jiwa N.M., Meijer C.J.L.M. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander. J. Pathol. 184:1997;353-356.
356. Murray P.G., Billingham L.J., Hassan H.T., et al. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood. 94:1999;442-447.
357. Fellbaum C., Hansmann M., Niedermeyer H., et al. Influence of Epstein-Barr virus genome on patient survival in Hodgkin's disease. Am. J. Clin. Pathol. 98:1992;319-323.
358. Herbst H., Dallenbach F., Hummel M., et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc. Natl. Acad. Sci. USA. 88:1991;4766-4770.
359. Pallesen G., Hamilton Dutoit S.J., Rowe M., Young L.S. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet. 337:1991;320.
360. Oudejans J.J., Jiwa N.M., Kummer J.A., et al. Activated cytotoxic T-cells as prognostic marker in Hodgkin's disease. Blood. 89:1997;1367-1382.
361. Willenbrock K., Roers A., Blohbaum B., Rajewsky K., Hansmann M.L. CD8(+) T-cells in Hodgkin's disease tumor tissue are a polyclonal population with limited clonal expansion but little evidence of selection by antigen. Am. J. Pathol. 157:2000;171-175.
362. Lee S.P., Constandinou C.M., Thomas W.A., et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood. 92:1998;1020-1030.
363. Frisan T., Sjöberg J., Dolcetti R., et al. Local suppression of Epstein-Barr virus (EBV) specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood. 86:(4):1995;1493-1501.
364. Chapman A.L., Rickinson A.B., Thomas W.A., et al. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 61:2001;6219-6226.
365. Burdin N., Peronne C., Banchereau J., Rousset F. Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J. Exp. Med. 177:1993;295-304.
366. Herbst H., Foss H.D., Samol J., Araujo I., Klotzbach H. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood. 87:(7):1996;2918-2929.
367. Bladergroen B.A., Meijer C.J., ten Berge R.L., et al. Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system. Blood. 99:2002;232-237.
368. Brink A.A.T.P., Oudejans J.J., Vandenbrule A.J.C., et al. Low P53 and high Bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance. Mod. Pathol. 11:1998;376-383.
369. Jiwa N.M., Kanavaros P., Van der Valk P., et al. Expression of c-myc and bcl-2 oncogene products in Reed-Sternberg cells independent of the presence of Epstein-Barr virus. J. Clin. Pathol. 46:1993;211-217.
370. Yoshizaki T., Sato H., Furukawa M., Pagano J.S. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA. 95:1998;3621-3626.
371. Oelmann E., Herbst H., Zuhlsdorf M., et al. Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood. 99:2002;258-267.
372. Murono S., Inoue H., Tanabe T., et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. USA. 98:2001;6905-6910.
373. Murono S., Yoshizaki T., Sato H., et al. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 60:2000;2555-2561.
374. Beck A., Pazolt D., Grabenbauer G.G., et al. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma: comparison with Hodgkin's disease. J. Pathol. 194:2001;145-151.
375. Simons M.J., Shanmugaratnam K. The biology of nasopharyngeal carcinoma. 1982;International Union Against Cancer, Geneva.
376. Pathmanathan R. Pathology. Chong V.F.H., Tsao S.Y. Nasopharyngeal carcinoma. 1997;6-13 Armour Publishing, Singapore.
377. Shanmugaratnam K., Sobin L.H. Histological typing of tumours of the upper respiratory tract and ear. 1991;Springer, Berlin.
378. Parkin D.M., Whelan S.L., Ferlany J., Raymond L., Young J. Cancer incidence in five continents. 1997;IARC Scientific Publications, Lyon.
379. Albeck H., Nielsen N.H., Hansen H.E., et al. Epidemiology of nasopharyngeal and salivary gland carcinoma in Greenland. Arct. Med. Res. 51:1992;189-195.
380. Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res. 34:1974;1189-1191.
381. Parkin D.M., Iscovich J. Risk of cancer in migrants and their descendants in Israel: II. Carcinomas and germ-cell tumours. Int. J. Cancer. 70:1997;654-660.
382. Jeannel D., Bouvier G., Hubert A. Nasopharyngeal cancer: an epidemiological approach to carcinogenesis. Cancer Surv. 33:1999;125-155.
383. Raab-Traub N. Epstein-Barr virus and nasopharyngeal carcinoma. Semin. Cancer Biol. 3:1992;297-307.
384. Pathmanathan R., Prasad U., Sadler R., Flynn K., Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. New Engl. J. Med. 333:1995;693-698.
385. Wu T.C., Mann R.B., Epstein J.I., et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. Am. J. Pathol. 138:1991;1461-1469.
386. Chen H.L., Lung M.M.L., Sham J.S.T., Choy D.T.K., Griffin B.E., Ng M.H. Transcription of BamHI-A region of the EBV genome in NPC tissue and B-cells. Virology. 191:1992;193-201.
387. Young L.S., Dawson C.W., Clark D., et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 69:1988;1051-1065.
388. Brooks L., Yao Q.Y., Rickinson A.B., Young L.S. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:1992;2689-2697.
389. Fahraeus R., Fu H.L., Ernberg I., et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int. J. Cancer. 42:1988;329-338.
390. Vere-Sempere F.J., Burgos J.S., Botella M.S., Morera C. Immunohistochemical expression of bcl-2 oncoprotein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival. Histol. Histopathol. 12:1997;9118.
391. Gulley M.L., Burton M.P., Allred D.C., et al. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma. Hum. Pathol. 29:1998;252-259.
392. Niemhom S., Kitazawa S., Murao S., Kunachak S., Maeda S. Co-expression of p53 and bcl-2 may correlate to the presence of Epstein-Barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma. Cancer Lett. 160:2000;199-208.
393. Wei M.X., Ooka T. A transforming function of the BARF1 gene encoded by Epstein-Barr virus. EMBO J. 8:1989;2897-2903.
394. Lee S.P., Chan A.T., Cheung S.T., et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J. Immunol. 165:2000;573-582.
395. Shibata D., Weiss L.M. Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140:1992;769-774.
396. Tokunaga M., Land C.E., Uemura Y., et al. Epstein-Barr virus in gastric carcinoma. Am. J. Pathol. 143:1993;1250-1254.
397. Takada K. Epstein-Barr virus and gastric carcinoma. Mol. Pathol. 53:2000;255-261.
398. Rowlands D.C., Ito M., Mangham D.C., et al. Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas. Br. J. Cancer. 68:1993;1014-1019.
399. Chang M.S., Lee J.H., Kim J.P., et al. Microsatellite instability and Epstein-Barr virus infection in gastric remnant cancers. Pathol. Int. 50:2000;486-492.
400. Imai S., Koizumi S., Sugiura M., et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc. Natl. Acad. Sci. USA. 91:1994;9131-9135.
401. Zur Hausen A., van den Brule A.J.C., Brink A.A.T.P., et al. Epstein-Barr virus (EBV) associated gastric carcinomas: a novel unique pattern of EBV latent gene expression. Cancer Res. 60:2000;2745-2748.
402. Weiss L.M., Movahed L.A., Butler A.E., et al. Analysis of lymphoepithelioma and lymphoepithelioma-like carcinomas for Epstein-Barr virus genomes by in situ hybridization. Am. J. Surg. Pathol. 13:1989;625-631.
403. Leung S.Y., Yuen S.T., Ho C.M., Kwong W.K., Chung L.P. Presence of Epstein-Barr virus in lymphoepithelioma-like carcinoma of the middle ear. J. Clin. Pathol. 51:1998;602-605.
404. Chan J.K.C., Yip T.T.C., Tsang W.Y.W., Poon Y.F., Wong C.S.C., Ma V.W.S. Specific association of Epstein-Barr virus with lymphoepithelial carcinoma among tumors and tumorlike lesions of the salivary gland. Arch. Pathol. Lab. Med. 118:1994;994-997.
405. Pittaluga S., Wong M.P., Ping Chung L., Loke S.L. Clonal Epstein-Barr virus in lymphoepithelioma-like carcinoma of the lung. Am. J. Surg. Pathol. 17:1993;678-682.
406. Leyvraz S., Henle W., Chahinian A.P., et al. Association of Epstein-Barr virus with thymic carcinoma. New Engl. J. Med. 312:1985;1296-1299.
407. Lee E.S., Locker J., Nalesnik M., et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. New Engl. J. Med. 332:1995;19-25.
408. McClain K.L., Leach C.T., Jenson H.B., et al. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. New Engl. J. Med. 332:1995;12-18.
409. Cruz I., van den Brule A.J.C., Brink A.A.T.P., et al. No direct role for Epstein-Barr virus in oral carcinogenesis: a study at the DNA, RNA and protein levels. Int. J. Cancer. 86:2000;356-361.
410. Taylor Y., Melvin W.T., Sewell H.F., Flannelly G., Walker F. Prevalence of Epstein-Barr virus in the cervix. J. Clin. Pathol. 47:1994;92-93.
411. Wong K.Y., Collins R.J., Srivastava G., Pittaluga S., Cheung A.N.Y., Wong L.C. Epstein-Barr virus in carcinoma of the cervix. Int. J. Gynecol. Pathol. 12:1993;224-227.
412. Hilton D.A., Brown L.J.R., Pringle J.H., Nandha H. Absence of Epstein-Barr virus in carcinoma of the cervix. Cancer. 72:1993;1946-1948.
413. Payne S., Kernohan N.M., Walker F. Absence of in situ hybridization evidence for latent- or lytic-phase Epstein-Barr virus infection of preinvasive squamous lesions of the cervix. J. Pathol. 176:1995;221-226.
414. Greenspan J.S., Greenspan D., Lennette E.T., et al. Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion. New Engl. J. Med. 313:1985;1564-1571.
415. Niedobitek G., Young L.S., Lau R., et al. Epstein-Barr infection in oral hairy leukoplakia: virus replication in the absence of a detectable latent phase. J. Gen. Virol. 72:1991;3035-3046.
416. Gilligan J., Rajadurai P., Resnick L., Raab-Traub N. Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia. Proc. Natl. Acad. Sci. USA. 87:1990;8790-8794.
417. Resnick L., Herbst J.S., Ablashi D.V., et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. J. Am. Med. Assoc. 259:1988;384-388.
418. Cleary M.L., Epstein M.A., Finerty S., et al. Individual tumors of multifocal EBV virus-induced malignant lymphomas in tamarins arise from different B-cell clones. Science. 228:1985;722-724.
419. Cox C., Chang S., Karran L., Griffin B., Wedderburn N. Persistent Epstein-Barr virus infection in the common marmoset (Callithrix jacchus). J. Gen. Virol. 77:1996;1173-1180.
420. Li L., Feichtinger H., Kaaya E., et al. Expression of Epstein-Barr virus related nuclear antigens and B-cell markers in lymphomas of SIV immunosuppressed monkeys. Int.J. Cancer. 55:1993;609-915.
421. Feichtinger H., Li S.L., Kaaya E., et al. A monkey model for Zepstein-Barr virus-associated lympohomagenesis in human acquired immunodeficiency syndrome. J. Exp. Med. 176:1992;281-286.
422. Cho Y.G., Ramer J., Rivailler P., et al. An Epstein-Barr related herpesvirus from marmoswet lymphomas. Proc. Natl. Acad. Sci. USA. 98:2001;1224-1229.
423. Ferreri M.G., Rivadeneire E.D., Jarrett R., et al. HV-MNE, a novel lymphocryptovius related to Epstein-Barr virus, induces lymphoma in New Zealand White rabbits. Blood. 98:2001;2193-2199.
424. Moghaddam A., Rosenzweig M., Lee-Parritz D., et al. An animal model for acute and persistent Epstein-Barr virus infection. Science. 276:1997;2030-2033.
425. Epstein M.A., Morgan A.J., Finerty S., Randle B.J., Kirkwood J.K. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature. 318:1985;287-288.
426. Niedobitek G., Agathanggelou A., Finerty S., et al. Latent Epstein-Barr virus infection in cottontop tamarins; a possible model for Epstein-Barr virus infection in humans. Am. J. Pathol. 145:1994;969-978.
427. Cox C., Naylor B.A., Mackett M., et al. Immunization of common marmosets with Epstein-Barr virus (EBV) envelope glycoprotein gp340: effect on viral shedding following EBV challenge. J. Med. Virol. 55:1998;255-261.
428. Pearson G., Dewey F., Klein G., Henle G., Henle W. Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens induced by the virus. J. Natl. Cancer Inst. 45:1970;989-995.
429. Gu S.Y., Huang T.M., Ruan L., et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev. Biol. Stand., Basel. 84:1995;171-177.
430. Fuzzati-Armentero, Duchosal M.A. Hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease. Histol. Histopathol. 13:1998;155-168.
431. Mauray S., Fuzatti-Armentero M.T., trouillet P., et al. Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL6. Eur. J. Immunol. 30:2000;2065-2073.
432. Johannessen I., Asgar M., Crawford D.H. Essential role for T-cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Br. J. Haematol. 109:2000;600-610.
433. Wagar E.J., Cromwell M.A., Shultz L.D., et al. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J. Immunol. 165:2000;518-527.
434. Guinnes M.E., Kenney J.L., Reiss M., Lacy J. Bcl-2 antisense oligonucleotide therapy of Epstein-Barr virus-associated lymphoproliferative diseases in severe combined immunodeficient mice. Cancer Res. 60:2000;5354-5358.
435. Rousselet G., Busson P., Billaud M., et al. Structure and regulation of the blast-2/CD23 antigen in epithelial cells from nasopharyngeal carcinoma. Int. Immunol. 2:1990;1159-1166.
436. Westphal E.M., Blackstock W., Feng W., Israel B., Kenney S.C. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 60:2000;5781-5788.
437. Meij P., Rickinson A.B., Leen A., et al. Identification and prevalence CD8+ T-cell responses directed against Epstein-Barr virus encoded latent membrane proteins 1 and latent membrane protein 2. Int. J. Cancer. 99:2002;93-99.
438. Dawson C.W., Eliopoulos A.G., Dawson J., Young L.S. BHRF1, a viral homologue of the bcl-2 oncogene, disturbs epithelial cell differentiation. Oncogene. 9:1995;69-77.
439. Dawson C.W., Dawson J., Jones R., Ward K., Young L.S. Functional differences between BHRF1, the Epstein-Barr virus-encoded Bcl-2 homologue, and Bcl-2 in human epithelial cells. J. Virol. 72:1998;9016-9024.
440. Ooka T. BARF-1 gene as an EBV encoded oncogene. EBV Rep. 8:2001;177-182.
441. Farina A., Santarelli R., Gonnella R., et al. The BFRF1 gene of Epstein-Barr virus encodes a novel protein. J. Virol. 74:2000;3235-3244.
442. Oudejans J.J., Jiwa N.M., Kummer J.A., et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood. 87:(9):1996;3844-3851.
443. Herbst H., Foss H.D., Samol J., et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood. 87:1996;2918-2929.
444. Cheah M.S.C., Ley T.J., Tronick S.R., Robbins K.C. Fgr proto-oncogene mRNA induced in B lymphocytes by Epstein-Barr virus infection. Nature. 319:1986;238-240.
445. Gutkind J.S., Link D.C., Katamine S., et al. A novel c-fgr exon utilized in Epstein-Barr virus-infected B lymphocytes but not in normal monocytes. Mol. Cell. Biol. 11:1991;1500-1507.